|
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Daily Nevirapine to Prevent Mother to Infant Transmission of HIV conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical research trials and Daily Nevirapine to Prevent Mother to Infant Transmission of HIV healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Daily Nevirapine to Prevent Mother to Infant Transmission of HIV. Daily Nevirapine to Prevent Mother to Infant Transmission of HIV Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Daily Nevirapine to Prevent Mother to Infant Transmission of HIV clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Daily Nevirapine to Prevent Mother to Infant Transmission of HIV condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Daily Nevirapine to Prevent Mother to Infant Transmission of HIV  Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Infants who are breast-fed by HIV infected mothers have an increased risk of becoming infected with HIV. Standard therapy for the prevention of HIV infections in infants included zidovudine (ZDV) prior to the onset of labor, a single dose of nevirapine (NVP) for women during labor, and a single dose of NVP for newborns given 72 hours after birth. This study will determine if giving low dose daily NVP to breastfed infants of HIV infected mothers, in addition to standard therapy, will be more effective than standard therapy alone at preventing HIV infections in these infants.
Details: This study will evaluate the safety and effectiveness of adding daily infant NVP to standard prevention measures to decrease vertical transmission of HIV. According to current statistics from the study site, approximately 70% of the pregnant HIV infected women in this study will have begun antenatal ZDV prior to the initiation of NVP at labor. The remaining 30% of the HIV infected women enrolled in this trial will have been previously undiagnosed. These women will be diagnosed with HIV infection either at the time they present to the delivery room in stage 1 of labor or immediately postpartum if they present for delivery late in labor and cannot provide informed consent for HIV screening prior to delivery. All infants will receive the standard does of NVP at 72 hours postpartum. Infants will then be randomized to receive either daily NVP and a daily multivitamin (MVI) or a daily MVI alone. Infants will take NVP/MVI or MVI alone during Weeks 2 to 6 postpartum. The primary outcome measure is infant HIV infection rates at 6 months. Two additional related cohorts of women will be followed for comparison: 1) an equal number of HIV uninfected women and their children will be enrolled for comparison of postpartum morbidity and mortality; and 2) consenting HIV infected women and their children who choose not to enroll in the clinical trial or are ineligible because they are not breastfeeding will be enrolled in an ancillary cohort.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria for Pregnant or Postpartum Mothers - HIV infected - Planning to breastfeed - Able to tolerate oral drugs and available for 12 months of postpartum follow-up Exclusion Criteria - Significant physical or emotional distress - Infant with serious or life threatening disease or severe fetal abnormality - Obstetrical complications affecting maternal health - Prior antiretroviral drugs (except antenatal ZDV or intrapartum NVP)
Total Enrollment: 1800
Location and Contact Information:
Overall Study Official:
RobertBollinger, Principal Investigator, Johns Hopkins University
BJ Medical College *Recruiting*
Pune, ,
India
Recruiting Mridula Phadke 91-20-553-8962
Additional Information:
Study ID Numbers: 5R01AI045462-04;
Study Start Date: August 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061321
Other Hiv Infections Studies:
1. A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
2. A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
3. Comparison of Three Different Initial Treatments, Not Using Protease Inhibitors, for HIV Infection
4. The Safety and Effectiveness of r-HuEPO in Patients with AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
5. A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Pune Clinical Trials
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
|
|
|
|
|
|
|
|
